Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 92

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 5
Chunk 92
---
334,194    
Cost of sales                                                           (3,594,146   )                              -              (3,594,146   )
Other income                                                            10,256,740                          1,343,062               8,913,678    
Other losses                                                              (351,646   )                     (1,226,108   )             874,462    
Loss on movement in contingent consideration                            (4,069,680   )                     (8,860,358   )           4,790,678    
General and administrative expenses                                    (14,638,013   )                    (13,039,246   )          (1,598,767   )
Research and development                                               (27,515,194   )                    (23,086,267   )          (4,428,927   )
Share-based payments                                                    (1,895,348   )                     (2,640,178   )             744,830    
Finance expenses                                                           (65,300   )                       (642,888   )             577,588    
Income tax expense                                                        (103,292   )                        (96,364   )              (6,928   )
Exchange differences on translation of foreign operations                  464,034                            202,956                 261,078    
Total comprehensive loss                                               (37,878,423   )                    (47,746,163   )           9,867,740    

Loss per share for loss attributable to the ordinary equity holders of the group:     Cents             Cents             $ Change      
----------------------------------------------------------------------------------------------------------------------------------------
Basic and diluted loss per share                                                         (1.76   )        (12.41   )          (10.65   )

Revenue from contracts with customers

Revenue from contracts with customers increased from A$299,228 in fiscal 2024 to A$3,633,422 in fiscal 2025 due to an increase in revenue received from Lantheus with respect to the DUNP19 trial Radiopharm is conducting on behalf of Lantheus. Revenue recognized from Lantheus was based on reimbursement for costs associated with the trials and milestones achieved throughout the trial.

Cost of sales

Cost of sales increased from nil in fiscal 2024 to $3,594,146 in fiscal 2025 due to an increase is the costs associated with respect to the DUNP19 trial Radiopharm is conducting on behalf of Lantheus.

Other income

Other income increased from A$1,343,062 in fiscal